Apogee Therapeutics has announced that its experimental antibody treatment, APG777, has successfully alleviated symptoms of atopic dermatitis in a mid-stage clinical trial. The treatment demonstrated efficacy comparable to two existing market treatments, Dupixent and Ebglyss, while offering a more convenient dosing schedule every 2-4 months compared to the twice-monthly and monthly injections of its competitors.
Source: https://www.statnews.com/2025/07/07/apogee-therapeutics-eczema-drug-study-results